GSK punts a failed cardio drug to a biotech startup — which has a new development strategy in mind
More than 3 years after losmapimod proved to be a turkey in a late-stage cardio study at GlaxoSmithKline, the drug has been dusted off and handed over to a startup, which has some new plans in mind for this therapy.
Researchers at Fulcrum have been probing the role that the DUX4 gene plays in triggering rare cases of facioscapulohumeral muscular dystrophy. They concluded that a selective p38α/β MAPK inhibitor could do the job on DUX4, and GSK had one on the back shelf it hadn’t touched in years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.